Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 409

1.

Cancer invasion regulates vascular complexity in a three-dimensional biomimetic model.

Pape J, Magdeldin T, Ali M, Walsh C, Lythgoe M, Emberton M, Cheema U.

Eur J Cancer. 2019 Aug 27;119:179-193. doi: 10.1016/j.ejca.2019.07.005. [Epub ahead of print]

PMID:
31470251
2.

Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.

Radtke JP, Giganti F, Wiesenfarth M, Stabile A, Marenco J, Orczyk C, Kasivisvanathan V, Nyarangi-Dix JN, Schütz V, Dieffenbacher S, Görtz M, Stenzinger A, Roth W, Freeman A, Punwani S, Bonekamp D, Schlemmer HP, Hohenfellner M, Emberton M, Moore CM.

PLoS One. 2019 Aug 26;14(8):e0221350. doi: 10.1371/journal.pone.0221350. eCollection 2019.

3.

First-in-human in vivo non-invasive assessment of intra-tumoral metabolic heterogeneity in renal cell carcinoma.

Tran M, Latifoltojar A, Neves JB, Papoutsaki MV, Gong F, Comment A, Costa ASH, Glaser M, Tran-Dang MA, El Sheikh S, Piga W, Bainbridge A, Barnes A, Young T, Jeraj H, Awais R, Adeleke S, Holt C, O'Callaghan J, Twyman F, Atkinson D, Frezza C, Årstad E, Gadian D, Emberton M, Punwani S.

BJR Case Rep. 2019 May 2;5(3). pii: 20190003. doi: 10.1259/bjrcr.20190003. Epub 2019 Mar 5.

4.

Salvage Local Treatments After Focal Therapy for Prostate Cancer.

Marra G, Valerio M, Emberton M, Heidenreich A, Crook JM, Bossi A, Pisters LL.

Eur Urol Oncol. 2019 Sep;2(5):526-538. doi: 10.1016/j.euo.2019.03.008. Epub 2019 Apr 15. Review.

PMID:
31412013
6.

Comparison of TRUS-Biopsy to Transperineal Template Mapping Biopsies Stratified by Multi-Parametric MRI Score within the PROMIS Trial.

Lovegrove C, Miah S, El-Shater Bosaily A, Bott S, Brown L, Burns-Cox N, Dudderidge T, Freeman A, Henderson A, Hindley R, Kaplan R, Kirkham A, Oldroyd R, Parker C, Persad R, Punwani S, Rosario D, Shergill I, Winkler M, Emberton M, Ahmed HU.

J Urol. 2019 Jul 23:101097JU0000000000000455. doi: 10.1097/JU.0000000000000455. [Epub ahead of print]

PMID:
31335254
7.

Dropping the GAD - just a fad? The case for a simpler, quicker, safer and cheaper prostate magnetic resonance imaging.

Emberton M.

BJU Int. 2019 Aug;124(2):183-184. doi: 10.1111/bju.14801. No abstract available.

PMID:
31321868
8.

Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS, Allen C, Emberton M, Moore CM, Kasivisvanathan V.

Nat Rev Urol. 2019 Jul 17. doi: 10.1038/s41585-019-0212-4. [Epub ahead of print] Review.

PMID:
31316185
9.

Protocol for a feasibility study of a cohort embedded randomised controlled trial comparing NEphron Sparing Treatment (NEST) for small renal masses.

Neves JB, Cullen D, Grant L, Walkden M, Bandula S, Patki P, Barod R, Mumtaz F, Aitchison M, Pizzo E, Ranieri V, Williams N, Wildgoose W, Gurusamy K, Emberton M, Bex A, Tran MGB.

BMJ Open. 2019 Jun 11;9(6):e030965. doi: 10.1136/bmjopen-2019-030965.

10.

Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis.

Kasivisvanathan V, Stabile A, Neves JB, Giganti F, Valerio M, Shanmugabavan Y, Clement KD, Sarkar D, Philippou Y, Thurtle D, Deeks J, Emberton M, Takwoingi Y, Moore CM.

Eur Urol. 2019 Sep;76(3):284-303. doi: 10.1016/j.eururo.2019.04.043. Epub 2019 May 24. Review.

PMID:
31130434
11.

Targeted biopsy of the prostate: does this result in improvement in detection of high-grade cancer or the occurrence of the Will Rogers phenomenon?

Bass EJ, Orczyk C, Grey A, Freeman A, Jameson C, Punwani S, Ramachandran N, Allen C, Emberton M, Ahmed HU.

BJU Int. 2019 May 13. doi: 10.1111/bju.14806. [Epub ahead of print]

PMID:
31081983
12.

The Evolution of MRI of the Prostate: The Past, the Present, and the Future.

Giganti F, Rosenkrantz AB, Villeirs G, Panebianco V, Stabile A, Emberton M, Moore CM.

AJR Am J Roentgenol. 2019 Aug;213(2):384-396. doi: 10.2214/AJR.18.20796. Epub 2019 Apr 30.

PMID:
31039022
13.

Role of MRI in planning radical prostatectomy: what is the added value?

Marenco J, Orczyk C, Collins T, Moore C, Emberton M.

World J Urol. 2019 Jul;37(7):1289-1292. doi: 10.1007/s00345-019-02762-2. Epub 2019 Apr 15.

PMID:
30993425
14.

Thermoresponsive Stiffness Softening of Hierarchically Porous Nanohybrid Membranes Promotes Niches for Mesenchymal Stem Cell Differentiation.

Wu L, Magaz A, Darbyshire A, Howkins A, Reynolds A, Boyd IW, Song H, Song JH, Loizidou M, Emberton M, Birchall M, Song W.

Adv Healthc Mater. 2019 May;8(10):e1801556. doi: 10.1002/adhm.201801556. Epub 2019 Apr 4.

PMID:
30945813
15.

VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient.

Johnston EW, Bonet-Carne E, Ferizi U, Yvernault B, Pye H, Patel D, Clemente J, Piga W, Heavey S, Sidhu HS, Giganti F, O'Callaghan J, Brizmohun Appayya M, Grey A, Saborowska A, Ourselin S, Hawkes D, Moore CM, Emberton M, Ahmed HU, Whitaker H, Rodriguez-Justo M, Freeman A, Atkinson D, Alexander D, Panagiotaki E, Punwani S.

Radiology. 2019 May;291(2):391-397. doi: 10.1148/radiol.2019181749. Epub 2019 Apr 2.

PMID:
30938627
16.

Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence.

Marconi L, Stonier T, Tourinho-Barbosa R, Moore C, Ahmed HU, Cathelineau X, Emberton M, Sanchez-Salas R, Cathcart P.

Eur Urol. 2019 Jul;76(1):27-30. doi: 10.1016/j.eururo.2019.03.007. Epub 2019 Mar 21.

PMID:
30904357
17.

To see or not to see - what renders prostate cancer visible?

Emberton M.

Nat Rev Urol. 2019 May;16(5):274-275. doi: 10.1038/s41585-019-0167-5. No abstract available.

PMID:
30867581
18.

New standards in prostate biopsy.

Marenco J, Kasivisvanathan V, Emberton M.

Arch Esp Urol. 2019 Mar;72(2):142-149. Review.

PMID:
30855015
19.

Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome.

Giganti F, Stabile A, Giona S, Marenco J, Orczyk C, Moore CM, Allen C, Kirkham A, Emberton M, Punwani S.

Magn Reson Imaging. 2019 May;58:143-147. doi: 10.1016/j.mri.2019.02.003. Epub 2019 Feb 12.

PMID:
30768957
20.

Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer.

Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, Dickinson L, Allen C, Punwani S, Jameson C, Freeman A, McCartan N, Montorsi F, Briganti A, Ahmed HU, Emberton M, Moore CM.

BJU Int. 2019 Sep;124(3):431-440. doi: 10.1111/bju.14710. Epub 2019 Mar 18.

PMID:
30753756

Supplemental Content

Loading ...
Support Center